Oncolytic HSV-1 virotherapy: Clinical experience and opportunities for progress

Balveen Kaur, E. Antonio Chiocca, Timothy P. Cripe

Research output: Contribution to journalArticlepeer-review

51 Scopus citations


Oncolytic virotherapy with mutants derived from Herpes simplex virus (HSV) type 1 exhibit significant antitumor effects in preclinical models. Several mutants have now been tested in clinical trials for a variety of cancer types, and all have been found to be safe. While there have been hints of antitumor efficacy with prolonged survival in some cases compared with historical controls, dramatic responses have been elusive. We review the clinical experience published to date and discuss some of the biologic factors that may be limiting for virus infection and spread, as well as new strategies currently under development to enhance antitumor efficacy.

Original languageEnglish (US)
Pages (from-to)1842-1851
Number of pages10
JournalCurrent Pharmaceutical Biotechnology
Issue number9
StatePublished - Jul 2012
Externally publishedYes


  • Angiogenesis
  • Cytokines
  • Extracellular matrix
  • Herpes simplex virus
  • Immune response
  • Oncolytic viruses
  • Tumor microenvironment

ASJC Scopus subject areas

  • Biotechnology
  • Pharmaceutical Science


Dive into the research topics of 'Oncolytic HSV-1 virotherapy: Clinical experience and opportunities for progress'. Together they form a unique fingerprint.

Cite this